EuMCV5 is under clinical development by Eubiologics and currently in Phase I for Neisseria meningitidis Infections. According to GlobalData, Phase I drugs for Neisseria meningitidis Infections have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EuMCV5’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EuMCV5 overview
EuMCV5 is under development for the prevention of Neisseria meningitidis infections. The vaccine candidate comprises of 5 serotypes of meningococcal polysaccharide (A, C, W-135,X and Y) which are conjugated to the CRM197 protein. It is administered through intramuscular route in the form of solution.
Eubiologics overview
Eubiologics is a biopharmaceutical company that develops and commercializes vaccines for bacterial epidemics. The company provides products such as Euvichol, an oral cholera prevention vaccine; and diphtheria toxin mutant, CRM197. It also provides contract research and manufacturing services, which includes cell line development, process scale-up optimization, process validation, analytical method development, cell bank production, QC testing and clinical material production services. Eubiologics spans expertise in manufacturing mammalian cell and microbial cell derived biopharmaceuticals such as recombinant biological products and antibody therapeutics. The company operates a research and development center and manufacturing facility in Chuncheon. Eubiologics is headquartered in Seoul, South Korea.
For a complete picture of EuMCV5’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
